Santhana G.T. Devaraj

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

Warren Fiskus, Sunil Sharma, Jun Qi et al. · Molecular Cancer Therapeutics · 2014 · 191 citations

Medicine, Molecular Biology, Oncology +17

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Kyungsoo Ha, Warren Fiskus, Dong Soon Choi et al. · Oncotarget · 2014 · 160 citations · Full text

Medicine, Oncology, Pharmacology +17

BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

Warren Fiskus, Sunil Sharma, Jun Qi et al. · Molecular Cancer Therapeutics · 2014 · 138 citations · Full text

Medicine, Oncology, Pharmacology +16

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Baohua Sun, Bhavin Shah, Warren Fiskus et al. · Blood · 2015 · 107 citations · Full text

Medicine, Oncology, Pharmacology +7

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

Warren Fiskus, S. Sharma, Saikat Saha et al. · Leukemia · 2014 · 96 citations · Full text

Medicine, Oncology, Pharmacology +14